Conversely, the CASP9 -712CT genotype/T allele of CASP9 -712C>T polymorphism significantly conferred reduced risk for the development of CML under codominant, dominant and over-dominant models. This evidence concerns the gene CASP9 and chronic myelogenous leukemia, BCR-ABL1 positive.